News Issued: May 7, 2024 (9:25am EDT) To view this online and get more information about Novavax Investor Relations visit: NOVAVAX TO HOST CONFERENCE CALL TO DISCUSS FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS ON MAY 10, 2024 GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024. Details of the event and replay are as follows: Conference call details: Date:                              May 10, 2024 Time:                                8:30 a.m. U.S. ET URL to register phone:      Dial-in number:                  (888) 664-6383 (Domestic) or (+1) (416) 764-8650 (International) Webcast:      ir.novavax.com/events * Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back. * Participants can also dial direct to be entered into the call by an Operator and will be prompted to request to join the Novavax, Inc. call. * To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast. Replay details: Date:                Available starting at 11:30 a.m. ET, May 10, 2024, until 11:59 p.m. U.S. ET, May 17, 2024 Dial-in number: (888) 390-0541 (Domestic) or (+1) (416) 764-8677 (International) Passcode:          414036# Webcast:              ir.novavax.com/events, until June 10, 2024 About Novavax Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Contacts: Investors  Erika Schultz 240-268-2022 [email protected] Media Giovanna Chandler 202-709-5563  [email protected] Novavax Logo (PRNewsfoto/Novavax) SOURCE Novavax, Inc.